Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Atea Pharmaceuticals Inc (NQ: AVIR ) 3.290 +0.050 (+1.54%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 78,569 Open 3.280 Bid (Size) 3.280 (12) Ask (Size) 3.290 (32) Prev. Close 3.240 Today's Range 3.246 - 3.310 52wk Range 2.765 - 4.600 Shares Outstanding 83,399,377 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 October 31, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 October 30, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Performance YTD +2.49% +2.49% 1 Month -1.20% -1.20% 3 Month +0.30% +0.30% 6 Month -17.75% -17.75% 1 Year +0.61% +0.61% More News Read More Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus September 13, 2024 Via Benzinga Exposures COVID-19 Recap: Atea Pharmaceuticals Q4 Earnings February 28, 2024 Via Benzinga Atea Pharmaceuticals Earnings Preview February 27, 2024 Via Benzinga Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session September 13, 2024 Via Benzinga Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 September 13, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway August 28, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update August 07, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 July 31, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus June 05, 2024 Via Benzinga Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 June 05, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference May 29, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 May 22, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire AVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024 May 14, 2024 Via InvestorPlace Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update May 14, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire 5 Under 10: Low Share Price, Debt Free, Lots Of Cash May 13, 2024 Via Talk Markets Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 May 07, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 April 29, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients March 27, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 28, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 February 21, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy January 09, 2024 Via Benzinga Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 January 08, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Atea Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
